Clinical Trial Update: Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cisplatin with or without an unspecified monoclonal antibody therapy in patients with metastatic or recurrent head and neck cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Monoclonal antibody therapy

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED